Answer extracted from the Proven Podcast — listen to the full episode below.
Why does the first drug cost $9 million but the second costs a penny?
The first drug to reach market costs $9 million because it must fund all research, clinical studies, and regulatory approval—but once that single pill is approved, the second pill costs only a penny to manufacture. Yet prices remain artificially high because insurance structures eliminate direct price competition between suppliers and patients.
This gap between innovation cost and production cost reveals the core problem in pharmaceutical pricing. The entire burden of funding research and development falls on the first approved drug. Once a company recovers that investment and moves to mass production, the marginal cost per unit becomes negligible.
The real barrier to lower prices, however, is how insurance intermediaries control the relationship between patients and drug makers. When insurers decide coverage, patients have no direct bargaining power. This eliminates the one force that typically drives prices down in any market: competition for customers based on price.
When patients pay directly, prices fall without insurance
The real-world proof came from GLP-1 weight loss drugs. Prices for these medications declined significantly over the last three years despite zero insurance coverage. Companies like Novo Nordisk and Eli Lilly competed directly for direct-pay customers, forcing them to lower prices to remain competitive.
This mirrors what David Goldhill describes as a structural truth: in healthcare systems where insurers act as middle-men, nobody in the system can profit by lowering prices. Providers cannot attract more patients by cutting costs because insurers control patient volume. Insurers have no reason to demand lower prices because patients don't see the bill. The only way to break this cycle is to remove the third-party payment layer entirely.
"Nobody in the healthcare system can make more money, can be more profitable by lowering their prices."
David Goldhill — Founder and CEO of Sesame, a healthcare marketplace. Goldhill spent decades as an entertainment executive, running television at Universal Studios and founding the Game Show Network, before pivoting to healthcare innovation after recognizing structural failures in American drug pricing and medical cost systems.
The GLP-1 example reveals what Goldhill explores in detail in this episode: when patients become direct consumers instead of insured beneficiaries, market economics reassert themselves. Prices move toward production cost rather than toward whatever the market will bear through insurance reimbursement.
See also
How much of healthcare spending goes directly to administrative costs of the payment system rather than actual medical care?
Administrative costs for the payment system account for 10–15% directly of the cost of care, meaning thousands of dollars per employee per year never reach actual medical treatment.
What is the lifetime cost burden for an average American employee and their family participating in the healthcare system?
In 2012, the lifetime healthcare cost for an average employee—including premiums, employer contributions, Medicare, and Medicaid—totaled approximately $1.2 million per person.
How does third-party payment insurance structure distort competition and pricing in healthcare markets?
Third-party payers control both pricing and patient volume, removing any incentive for providers to compete on price. Unlike any other market, healthcare suppliers cannot attract customers by lowering costs.
Key takeaways
- The first drug approval absorbs $9 million in research and regulatory costs; subsequent pills cost pennies to produce.
- Insurance intermediaries eliminate price-based competition by controlling both payment and patient access.
- When patients pay directly, as with uninsured GLP-1 drugs, prices fall through genuine market competition.
- Removing third-party payment structures is the only way to align healthcare pricing with actual production costs.